Report overview
This report contains market size and forecasts of Non-Small Cell Lung Cancer Treatment (NSCLC) in Global, including the following market information:
Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Revenue, 2018-2023, 2023-2032, ($ millions)
Global top five companies in 2022 (%)
The global Non-Small Cell Lung Cancer Treatment (NSCLC) market was valued at US$ million in 2022 and is projected to reach US$ million by 2032, at a CAGR of % during the forecast period 2023-2032.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2032.
Angiogenesis Inhibitor Segment to Reach $ Million by 2032, with a % CAGR in next six years.
The global key manufacturers of Non-Small Cell Lung Cancer Treatment (NSCLC) include AbbVie Inc., Astellas Pharma, AstraZeneca, Avid Bioservices Inc., Bayer Healthcare, Biogen Inc., Blueprint Medicines Corp, Eli Lilly and Company and Merck & co Inc., etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-Small Cell Lung Cancer Treatment (NSCLC) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market, by Type, 2018-2023, 2023-2032 ($ millions)
Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Segment Percentages, by Type, 2022 (%)
Angiogenesis Inhibitor
Epidermal Growth Factor Receptor Blocker
Kinase Inhibitor
Microtubule Stabilizer
Folate Antimetabolites
Others
Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market, by Application, 2018-2023, 2023-2032 ($ millions)
Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Segment Percentages, by Application, 2022 (%)
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market, By Region and Country, 2018-2023, 2023-2032 ($ Millions)
Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Small Cell Lung Cancer Treatment (NSCLC) revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-Small Cell Lung Cancer Treatment (NSCLC) revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie Inc.
Astellas Pharma
AstraZeneca
Avid Bioservices Inc.
Bayer Healthcare
Biogen Inc.
Blueprint Medicines Corp
Eli Lilly and Company
Merck & co Inc.
Novartis
Pfizer Inc.
